FDA expands authorisation of two monoclonal antibodies for treatment and post-exposure prevention of COVID-19 to paediatric patients Read more
New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust efficacy and long-term prevention Read more
ZD7442 reduces risk of developing severe COVID-19 or death in Tackle phase-III outpatient treatment trial Read more